Alkol ve Naltrekson etkileşimi

Precipitation of Opioid Withdrawal : Opioid-dependent and opioid-using patients, including those being treated for alcohol dependence, should be opioid-free before starting naltrexone for extended-release injectable suspension treatment, and should notify healthcare providers of any recent opioid use.

To prevent occurrence of precipitated withdrawal in patients dependent on opioids, or exacerbation of a pre-existing subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone for extended-release injectable suspension treatment.

Patients treated for alcohol dependence with naltrexone for extended-release injectable suspension should also be assessed for underlying opioid dependence and for any recent use of opioids prior to initiation of treatment with naltrexone for extended-release injectable suspension.

Precipitated opioid withdrawal has been observed in alcohol-dependent patients in circumstances where the prescriber had been unaware of the additional use of opioids or co-dependence on opioids.

In the 24-week, placebo-controlled pivotal trial in 624 alcohol-dependent patients, adverse events involving depressed mood were reported by 10% of patients treated with naltrexone for extended-release injectable suspension 380 mg, as compared to 5% of patients treated with placebo injections.